Serum Institute conducting phase III clinical trial of BCG vaccine: DBT

Serum Institute conducting phase III clinical trial of BCG vaccine: DBT

Serum Institute conducting phase III clinical trial of BCG vaccine: DBT About 6,000 health workers and high-risk individuals including those in close contact of COVID-19 patients have been enrolled in a clinical trial to determine if the recombinant Bacillus Calmette-Guerian (rBCG) can boost immunity to fight against the virus, the statement added.